At the half-way point of 2021, Genmab-developed drug Darzalex is close to achieving triple-blockbuster status, after a significant growth in sales compared to last year.
Johnson & Johnson report that sales of Darzalex in Q2 alone totaled USD 1.43bn, up from USD 901m for the same period last year. This brings the total sales for the first half of 2021 up to USD 2.8bn.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.